How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Indiana

NMN and NR: What Indiana Patients Need to Know

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors that feed into the salvage biosynthetic pathway to replenish cellular nicotinamide adenine dinucleotide levels. NAD+ declines roughly 50% between ages 40 and 60, a trajectory linked to mitochondrial dysfunction, DNA repair deficits, and metabolic deterioration 1. Both compounds aim to reverse that decline, though by slightly different enzymatic routes.

How NMN Differs from NR

NMN is phosphorylated one step closer to NAD+ in the biosynthetic chain. After oral dosing, NMN can be converted to NR extracellularly via CD73, then re-phosphorylated inside the cell, or it may enter cells directly through the SLC12A8 transporter identified in murine intestinal tissue 2. NR, by contrast, enters cells through equilibrative nucleoside transporters and is phosphorylated to NMN by nicotinamide riboside kinases (NRK1 and NRK2) 3. In practice, both compounds raise whole-blood NAD+ levels in humans, though head-to-head comparative data remain limited.

Regulatory Status

Neither NMN nor NR holds FDA approval as a prescription drug. NR is marketed as a dietary supplement (notably as Niagen by ChromaDex), while NMN's supplement status has been subject to regulatory dispute. In November 2022, the FDA issued a response indicating NMN may not qualify as a dietary supplement because it was first studied as a new drug candidate 4. This has pushed some patients toward compounded NMN obtained via 503A pharmacies, which operate under section 503A of the Federal Food, Drug, and Cosmetic Act 5.

Telehealth Prescribing in Indiana

Indiana law permits telehealth prescribing for NMN and NR when a valid provider-patient relationship is established. A licensed prescriber (MD, DO, NP, or PA) can evaluate you via synchronous audio-video visit and, if clinically appropriate, transmit a prescription to a compounding pharmacy.

Indiana Telehealth Regulations

The Indiana Medical Licensing Board recognizes telehealth encounters as equivalent to in-person visits for prescribing purposes, provided the encounter uses real-time interactive audio and video 6. Store-and-forward-only encounters do not satisfy Indiana's prescribing standard for new patients. After the initial synchronous visit, follow-up consultations may use asynchronous communication at the prescriber's discretion.

What Happens During the Visit

A typical consultation lasts 15 to 30 minutes. The prescriber reviews your health history, current medications, and goals for NAD+ support. They will order baseline labs (discussed below), discuss dosing, and select a compounding pharmacy. Many telehealth platforms that serve Indiana patients partner directly with national 503A pharmacies that ship to all 50 states 5.

Cost of the Telehealth Visit

Initial consultations typically range from $99 to $199. Some platforms bundle the visit fee with the first month of compounded NMN. Because Indiana Medicaid does not cover NMN or NR for longevity indications, patients pay out of pocket for both the visit and the medication.

Required Labs Before Starting NMN or NR

Prescribers ordering compounded NMN in Indiana typically require baseline bloodwork to screen for contraindications and to establish a measurable starting point for therapy.

Standard Pre-Treatment Panel

A common lab order includes a comprehensive metabolic panel (CMP), complete blood count (CBC), fasting lipid panel, fasting glucose or HbA1c, and liver function tests (ALT, AST). Some longevity-focused clinicians also order intracellular NAD+ levels or whole-blood NAD+ assays, though commercial availability of validated NAD+ testing varies 7.

Why Liver and Kidney Markers Matter

NMN and NR are metabolized through hepatic and renal pathways. A 2021 clinical trial by Yoshino et al. In postmenopausal women with prediabetes (N=25) documented that 250 mg/day NMN for 10 weeks improved skeletal muscle insulin signaling without elevating liver enzymes 8. Monitoring ALT and AST at baseline and at 8 to 12 weeks confirms hepatic tolerability in the individual patient. Renal function markers (BUN, creatinine, eGFR) are checked because impaired clearance could alter metabolite kinetics.

Follow-Up Lab Timing

Most prescribers recheck labs at 8 to 12 weeks, then every 6 months if values remain stable. A randomized placebo-controlled trial of NR (1,000 mg/day for 6 weeks, N=40) found no clinically significant adverse changes in blood chemistry panels, supporting the relative safety of NAD+ precursors at standard doses 9.

503A Compounding Pharmacies and Indiana

Section 503A of the FDCA allows licensed pharmacies to compound patient-specific prescriptions without FDA pre-approval of the finished product. This is the primary legal pathway for dispensing compounded NMN in Indiana.

How 503A Compounding Works

A 503A pharmacy receives an individual prescription from your provider, compounds the NMN formulation to order, and ships it directly to you. The pharmacy must hold a valid Indiana Board of Pharmacy license or, if located out of state, a non-resident pharmacy license 5. Compounding must comply with USP <795> standards for nonsterile preparations 10.

Verifying Pharmacy Credentials

Before filling a prescription, confirm the pharmacy's license status through the Indiana Professional Licensing Agency (IPLA) online verification portal. Out-of-state 503A pharmacies shipping to Indiana addresses must register as non-resident pharmacies with the Indiana Board of Pharmacy.

Available Formulations

Compounded NMN typically comes as oral capsules (125 mg, 250 mg, or 500 mg) or sublingual tablets designed for buccal absorption. Sublingual delivery may bypass first-pass hepatic metabolism, though human bioavailability comparisons between oral and sublingual NMN are not yet established in peer-reviewed trials 11.

Dosing, Safety, and Clinical Evidence

The evidence base for NMN and NR in humans is growing but still consists mostly of small, short-duration trials. Indiana prescribers anchor dosing on published safety data and emerging efficacy signals.

Standard Dosing Ranges

Most clinicians start NMN at 250 mg once daily, taken in the morning. Doses may be increased to 500 mg or, less commonly, 1,000 mg daily based on patient response and lab trends. The Yoshino et al. Trial used 250 mg/day and demonstrated improved muscle insulin sensitivity without dose-limiting side effects 8. For NR, the CHROMADEX-sponsored study by Martens et al. (N=24 lean, healthy adults) showed that 1,000 mg/day NR for 6 weeks raised NAD+ by approximately 60% and was well tolerated 12.

Key Clinical Trials

A 12-week randomized controlled trial by Yi et al. (N=80 healthy middle-aged adults) reported that 300 mg, 600 mg, or 900 mg/day NMN all significantly increased blood NAD+ levels with a dose-response relationship 13. Participants across all dose groups tolerated the intervention without serious adverse events. Separately, Dollerup et al. (N=40 obese men) tested 2,000 mg/day NR for 12 weeks and found no improvement in insulin sensitivity, although NAD+ levels rose substantially 14. These mixed efficacy results reflect the current state of the field: NAD+ repletion is consistent, but downstream clinical benefits vary by population and endpoint.

Side Effects

Reported side effects across published trials include mild flushing, gastrointestinal discomfort, and transient headache. A systematic review of NR supplementation studies noted that adverse events were generally mild and self-limiting, with no pattern of serious organ toxicity 15. Flushing, when it occurs, is typically less severe than that caused by niacin (nicotinic acid), because NMN and NR do not directly activate the GPR109A receptor responsible for the classic niacin flush 16.

Drug Interactions

Prescribers should review concomitant medications that affect NAD+ metabolism. PARP inhibitors (olaparib, niraparib) deplete NAD+; combining them with NMN could theoretically blunt PARP inhibitor efficacy, though no clinical interaction data exist 17. CD38 inhibitors such as daratumumab can reduce NAD+ consumption, potentially augmenting the effects of supplementation 18.

Who Can Prescribe NMN/NR in Indiana

Indiana licensing rules determine which providers can write prescriptions for compounded NMN.

MDs and DOs

Physicians with an active Indiana medical license have full prescriptive authority and can order compounded NMN without collaborative agreements or supervisory requirements.

Nurse Practitioners

Indiana NPs must hold a collaborative practice agreement with a physician in order to prescribe. As of Indiana Code IC 25-23-1, NPs with this agreement in place can prescribe compounded NAD+ precursors, including NMN, provided it falls within their scope of practice 6.

Physician Assistants

PAs in Indiana prescribe under a supervisory agreement with a physician. The supervising physician does not need to be physically present at the time of prescribing but must be available for consultation per Indiana Administrative Code 844 IAC 2.2.

Cost and Insurance Coverage in Indiana

NAD+ precursor therapy is almost entirely self-pay in Indiana. Understanding the cost structure helps patients plan accordingly.

Why Insurance Rarely Covers NMN or NR

Neither NMN nor NR is FDA-approved as a drug, and longevity or anti-aging indications fall outside most formulary categories. Indiana Medicaid specifically excludes coverage for NMN and NR when prescribed for longevity purposes. Commercial insurers (Anthem BCBS Indiana, UnitedHealthcare, Cigna) likewise do not list compounded NMN on their formularies 19.

Monthly Cost Breakdown

The telehealth consultation runs $99 to $199 for the initial visit and $49 to $99 for follow-ups. Compounded NMN capsules (250 mg, 30-day supply) cost $80 to $150 from most 503A pharmacies. Higher doses or sublingual formulations can reach $200 to $250 per month. Lab work through direct-to-consumer panels costs $50 to $150 per draw, depending on the number of analytes.

Strategies to Reduce Cost

Some telehealth platforms offer subscription models that bundle visits, labs, and medication into a single monthly fee. Patients can also compare pricing across multiple 503A pharmacies, as compounded medication costs vary significantly between vendors. OTC NR supplements (e.g., Niagen) provide an alternative for patients who do not require a compounded formulation, typically at $40 to $60 per month for 300 mg/day.

Shipping and Delivery Timelines

After a telehealth visit, the prescription is transmitted electronically to the selected 503A pharmacy. Compounding and shipping typically take 7 to 14 business days for standard delivery within Indiana.

Factors That Affect Delivery Speed

Custom compounding adds 3 to 5 business days compared to dispensing a pre-made product. Pharmacies in adjacent states (Ohio, Illinois, Michigan, Kentucky) often have established shipping routes to Indiana addresses. Express shipping options can reduce total delivery time to 5 to 7 business days at an additional $15 to $30 cost.

Prescription Transfers

Indiana Board of Pharmacy regulations allow prescription transfers between licensed pharmacies. If you want to move your NMN prescription from an out-of-state 503A pharmacy to an Indiana-based pharmacy (or vice versa), both pharmacies must agree to the transfer and document it per 856 IAC 1-35. Compounded prescriptions are limited to the original number of authorized refills on the prescription, typically a 90-day supply with refills.

NAD+ Biology and Why It Matters

Understanding NAD+ physiology explains why clinicians prescribe NMN or NR in the first place.

The NAD+ Decline

NAD+ participates in over 500 enzymatic reactions, including those catalyzed by sirtuins (SIRT1 through SIRT7), poly(ADP-ribose) polymerases (PARPs), and CD38 1. Age-related NAD+ depletion has been documented in human skeletal muscle, brain, and liver tissue. Camacho-Pereira et al. Demonstrated that CD38 expression increases with age and is a primary driver of NAD+ decline in mice 18.

Sirtuin Activation

Sirtuins are NAD+-dependent deacetylases linked to DNA repair, mitochondrial biogenesis, and inflammation control. SIRT1 activation by NAD+ repletion improved metabolic parameters in mouse models of diet-induced obesity 20. Human translation remains a research priority, and the Yoshino et al. 2021 trial provided early evidence that NMN supplementation activates this pathway in human skeletal muscle 8.

Clinical Relevance for Indiana Patients

Indiana ranks 38th nationally for adult obesity prevalence, with 36.8% of adults classified as obese per 2023 CDC BRFSS data 21. Metabolic dysfunction associated with obesity accelerates NAD+ depletion, making the population particularly relevant for NAD+ precursor research. Prescribers in Indiana often frame NMN supplementation as one component of a broader metabolic optimization strategy that includes dietary modification, exercise, and pharmacotherapy where indicated.